
The study analyzed 1012 metastatic castration-resistant prostate cancer (mCRPC) tissue samples to identify gene expression-based pathways associated with clinical outcomes. Five key pathway clusters were found, with loss of AR signaling, high proliferation, and glycolysis/mTOR signaling being adverse prognostic factors. AR signaling inhibitors did not permanently target these pathways, suggesting the need for more effective treatments. The findings can guide clinical prognostication.
Like
Save
Share